TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23907471
Drug: Clinical worsening
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical worsening (defined as worsening functional class, a ≥ 15% reduction in 6-min walk distance, all-cause hospitalization, or introduction of parenteral prostacyclin analog therapy)
Study: 23907731
Drug: Serum B-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum B-type natriuretic peptide (BNP) test with a cutoff of >364 pg/mL
Study: 23907731
Drug: Serum B-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum B-type natriuretic peptide (BNP) test with a cutoff of ≤ 182 pg/mL
Study: 23907766
Drug: Vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine sulfate liposome injection (VSLI) at a maximum tolerated dose of 2.25 mg/m² once per week without a dose cap
Study: 30239252
Drug: Vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine sulfate liposome injection (VSLI)
Study: 23909727
Drug: Omega-3 polyunsaturated
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 polyunsaturated fatty acids (PUFA) added to parenteral nutrition
Study: 23912473
Drug: Tapentadol prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol prolonged release (PR; 50-250 mg twice daily)
Study: 23912473
Drug: Tapentadol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol treatment
Study: 23912587
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with whole leukemia cells (up to 6 vaccines initiated between days 30 and 45 after transplantation)
Study: 23912763
Drug: Anti-inflammatory strategies
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory strategies tested on the graft ex vivo during islet culture and/or on the graft site in vivo early after islet infusion.
Study: 23915500
Drug: AA homozygotes
Normalized name: HOMOZYGOUS YUCATAN MINIATURE PIG ATAXIA TELANGIECTASIA MUTATED (ATM) GENE DISRUPTED BY A ATM-NEO RDNA CONSTRUCT IN EXON 57
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA homozygotes of rs2906569 (minor allele G, alternate allele A) at intron 1
Study: 23915500
Drug: CC homozygotes
Normalized name: HOMOZYGOUS YUCATAN MINIATURE PIG ATAXIA TELANGIECTASIA MUTATED (ATM) GENE DISRUPTED BY A ATM-NEO RDNA CONSTRUCT IN EXON 57
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC homozygotes of rs2301963 (minor allele A, alternate allele C) at exon 3
Study: 23917460
Drug: CYP phenotyping
Normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP phenotyping cocktail (50 mg tramadol, 20 mg omeprazole, 25 mg losartan, 200 mg caffeine) administered as a single oral dose.
Study: 23921878
Drug: Ultra low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultra low-dose OCP (1.0 mg norethindrone acetate and 10 micrograms ethinyl E2)
Study: 23924590
Drug: 2010/11 seasonal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2010/11 seasonal, trivalent influenza vaccine (TIV)
Study: 23924590
Drug: AS03 adjuvanted
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03 adjuvanted H1N1 vaccine
Study: 23924602
Drug: Exocrine pancreatic
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exocrine pancreatic insufficiency (EPI) defined by FE-1 concentration <200 μg/g
Study: 23924602
Drug: Severe exocrine
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe exocrine pancreatic insufficiency (EPI) defined by FE-1 concentration <100 μg/g
Study: 23924639
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy sequencing after cessation of breastfeeding
Study: 23928873
Drug: Discontinuation rate
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation rate
Study: 23929075
Drug: Hypo-osmolar 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypo-osmolar 0.1% riboflavin solution
Study: 23929075
Drug: Iso-osmolar 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iso-osmolar 0.1% riboflavin solution
Study: 23929075
Drug: Post-treatment monitoring
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment monitoring
Study: 23929949
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (1.35 × 10(5) PfSPZ), 5 doses
Study: 23929949
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (1.35 × 10(5) PfSPZ), 4 doses
Study: 23930209
Drug: Everolimus 5
Normalized name: everolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 5 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Study: 23930209
Drug: Everolimus 7.5
Normalized name: everolimus 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 7.5 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Study: 23930209
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day + Mitomycin C 5 mg/m² every 3 weeks
Study: 23932335
Drug: Double negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double negative for oestrogen- and progesterone receptors (ER/PR loss)
Study: 23932458
Drug: Asthma Control
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma Control Questionnaire (ACQ) administered at 8 visits
Study: 23938372
Drug: Staging laparoscopy
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staging laparoscopy (S-LPS) before primary debulking surgery (PDS) or neoadjuvant treatment (NACT)
Study: 23939283
Drug: Dose-dense ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-dense ixabepilone (40 mg/m2 every 14 days with granulocyte-colony stimulating factor)
Study: 23939283
Drug: Dose-dense FEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense FEC (5-fluorouracil 600 mg/m2, epirubicin 90 mg/m2, cyclophosphamide 600 mg/m2 every 14 days with granulocyte-colony stimulating factor)
Study: 23939368
Drug: Oral Rapid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Rapid Test (ORT)
Study: 23939898
Drug: Voriconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (400 mg every 12 h on day 1, followed by 200 mg every 12 h for 3 days)
Study: 23940128
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human PRL (r-hPRL) 60 μg/kg every 12 hours for 17 days
Study: 23942767
Drug: MVD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVD and CAD alone or in combination with PAH
Study: 23945372
Drug: Larger ex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger ex vivo capsules in baseline CSF
Study: 23945372
Drug: Capsule size
Normalized name: Empty Capsule Size 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule size
Study: 23945372
Drug: CSF capsule
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF capsule shedding
Study: 23947389
Drug: Switch antipsychotic
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch antipsychotic plus healthy lifestyle education (HLE)
Study: 23947389
Drug: Add metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add metformin plus healthy lifestyle education (HLE)
Study: 23947389
Drug: Healthy lifestyle
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy lifestyle education (HLE) with no medication change
Study: 23948110
Drug: Drug eluting
Normalized name: Drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug eluting balloon (DEB)
Study: 23949214
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU HCG daily for 7 days
Study: 23953882
Drug: Sequential arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential arm (starting on day 14)
Study: 23953988
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide (iv LCM) at a loading dose of 400 mg over 30 min, followed by a mean maintenance dose of 400 mg per day
Study: 23953988
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide (iv LCM)
Study: 23954889
Drug: Pomalidomide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (2.5 mg/d), cyclophosphamide (50 mg every other day), prednisone (50 mg every other day) for 6 cycles, followed by maintenance therapy.
Study: 27101285
Drug: Anti-angiogenic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-angiogenic therapy
Study: 23961354
Drug: Department of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Department of Health pamphlet about breast cancer and treatment
Study: 23963055
Drug: Escalating doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of transdermal nicotine (mean NRT dose 32.7 mg/d; range, 7-56 mg/d)
Study: 23963055
Drug: Escalating doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of transdermal nicotine
Study: 23965261
Drug: Motivational pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational pharmacotherapy
Study: 23966428
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Ca + 400 IU vitamin D3/d (Calcium/Vitamin D Trial)
Study: 23968316
Drug: Patient training
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient training programme involving the provision of information and practical training concerning their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust their anticoagulant dose.
Study: 23969187
Drug: Metreleptin (0.22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (0.22 mg/kg/d) for 12 months
Study: 23969187
Drug: Metreleptin treatment
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin treatment for 12 months
Study: 23969281
Drug: Actions taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actions taken to relieve withdrawal symptoms (e.g., nicotine use)
Study: 23969281
Drug: Withdrawal symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal symptoms (e.g., anxiety, cannabis craving)
Study: 23970725
Drug: Mifepristone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone treatment
Study: 23971740
Drug: Calcitriol 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.75 mcg/day
Study: 23971740
Drug: Calcitriol +
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol + Lisinopril
Study: 23971740
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Lisinopril
Study: 23973693
Drug: Highest HDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest HDL-C quintile among subjects with LDL-C <70 mg/dl
Study: 23975665
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m² at week 1, then 250 mg/m²/week) and Gemcitabine (1 g/m² on day 1, 8 and 15 every 4 weeks)
Study: 23976960
Drug: Trivalent surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent surface antigen, inactivated influenza vaccine (15 µg hemagglutinin of each virus strain)
Study: 23976960
Drug: Trivalent surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent surface antigen, inactivated influenza vaccine
Study: 23978163
Drug: CBMNC transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBMNC transplantation and rehabilitation therapy
Study: 23978163
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBMNC and UCMSC transplantation and rehabilitation therapy
Study: 23978163
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rehabilitation therapy only)
Study: 23978364
Drug: Newer agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer agents (prasugrel or ticagrelor)
Study: 23979288
Drug: Lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification and medical therapy
Study: 23979353
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy for 12 months
Study: 23979733
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (RPV) 25 mg every 24 h for 11 or 12 days plus Dolutegravir (DTG) 50 mg every 24 h for 5 days
Study: 23979733
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (RPV) 25 mg every 24 h for 11 or 12 days plus GSK1265744 30 mg every 24 h for 12 days
Study: 23979733
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) 50 mg every 24 h for 5 days
Study: 23979733
Drug: GSK1265744 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 (30 mg every 24 h for 12 days)
Study: 23980906
Drug: Betaine HCl
Normalized name: betaine HCl
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine HCl (1500 mg orally with 90 mL of water)
Study: 23982845
Drug: Ocriplasmin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin (125 μg)
Study: 23982845
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ocriplasmin injection)
Study: 23983212
Drug: Intravenous zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zanamivir 600 mg twice daily for up to 10 days
Study: 23983245
Drug: Multielectrode radiofrequency
Normalized name: SUPER-VIAL HYPERLYTE MULTIELECTROLYTE CONC INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multielectrode radiofrequency (MER) system with procedural changes (therapeutic vitamin K antagonist and heparin, submerged loading of the catheter, deactivation of either distal or proximal electrode)
Study: 23983684
Drug: 0.7 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 μg/kg dexmedetomidine
Study: 23983823
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy plus STn-KLH vaccine
Study: 23983823
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy plus STn-KLH vaccine with median or greater antibody response
Study: 23984046
Drug: Leucine +
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine + phenylalanine (1 mmol/kg fat free body mass each) + 25 g glucose
Study: 23984082
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg mifepristone daily for 3 months
Study: 23984082
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg mifepristone daily for 3 months
Study: 23984185
Drug: 250 μCi
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μCi of (131)I/mL thyroid tissue, corrected by 24-RAIU values (Group 1)
Study: 23984185
Drug: 200 μCi
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μCi of (131)I/mL/24-RAIU (Group 2, historical control)
Study: 23985703
Drug: Benidipine combined
Normalized name: manidipine
DrugBank: Manidipine (DB09238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine combined with β-blocker (BB)
Study: 23985703
Drug: Benidipine combined
Normalized name: manidipine
DrugBank: Manidipine (DB09238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine combined with thiazide diuretic (TD)
Study: 23985703
Drug: Benidipine combined
Normalized name: manidipine
DrugBank: Manidipine (DB09238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine combined with angiotensin receptor blocker (ARB)
Study: 23986161
Drug: Calcipotriene plus
Normalized name: Calcipotriene
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriene plus betamethasone dipropionate topical suspension
Study: 23986162
Drug: Apremilast 20
Normalized name: apremilast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 20 mg BID for 12 weeks
Study: 23988361
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with 6 months of anticoagulation and 24 months of compression stockings
Study: 23989950
Drug: Pazopanib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (800 mg daily continuously with a 28-day cycle)
Study: 23991111
Drug: Interleukin 1
Normalized name: Interleukin 13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin 1 receptor antagonist (IL-1RA)
Study: 23993936
Drug: Ondansetron administration
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron administration
Study: 23993936
Drug: Volume of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume of intravenous fluids administered
Study: 23994660
Drug: Sertraline 50mg
Normalized name: sertraline 50 MG
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline 50mg to 200mg/day
Study: 23999023
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of modifiable vascular risk factors and secondary prevention of stroke recurrence
Study: 24001117
Drug: Using at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using at least 1 other abortive medication with triptan
Study: 24002496
Drug: Quizartinib administered
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib administered orally at escalating doses of 12 to 450 mg/day
Study: 24002500
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg orally on days 1 through 21 every 28 days until disease progression or intolerance
Study: 24004118
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT screening in the PanCan cohort
Study: 24004118
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT screening in the BCCA cohort
Study: 24004540
Drug: Twice-daily Ropinirole
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily Ropinirole prolonged release (RPR)
Study: 24004540
Drug: Once-daily Ropinirole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily Ropinirole prolonged release (RPR)
Study: 24004540
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (once-daily and twice-daily RPR)
Study: 24004642
Drug: DAPT discontinuation
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT discontinuation
Study: 24004667
Drug: Bortezomib, dexamethasone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib, dexamethasone, and rituximab (BDR) combination therapy
Study: 24005614
Drug: Sorafenib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib at a dose of 800 mg daily
Study: 24006858
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at a dosage of 40 ppm
Study: 24007746
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m², Cyclophosphamide 600 mg/m², Trastuzumab 4 mg/kg (loading dose) on day 1 and 2 mg/kg on days 1, 8, and 15 during chemotherapy, followed by Trastuzumab 6 mg/kg every three weeks for 1 year.
Study: 24007819
Drug: Bevacizumab (7.5mg/kg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5mg/kg, day 1), weekly paclitaxel (80 mg/m(2) days 1, 8, 15), and carboplatin (AUC6, day 1) intravenously q3w for 6-8 cycles, followed by single-agent bevacizumab for 1 year.
Study: 24008739
Drug: PCV13 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 (1 dose)
Study: 24013510
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and capecitabine (first-line combination treatment)
Study: 24013904
Drug: Capecitabine 650
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 650 mg/m(2) twice daily and everolimus 5 mg twice daily
Study: 24014245
Drug: Carfilzomib, lenalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) at maximum planned dose (MPD)
Study: 24014245
Drug: Carfilzomib, lenalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in bortezomib-refractory patients
Study: 24014245
Drug: Carfilzomib, lenalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in lenalidomide-refractory patients
Study: 24014245
Drug: Carfilzomib, lenalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) at MPD
Study: 24015953
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of dexamethasone in 2 ml saline (treatment group)